|
N.A. Demidov
Dipeptyl peptidase type 4 inhibitors for modern therapy of type 2 diabetes mellitus
|
№12 / 2023
|
|
L.S. Aramisova, I.B. Zhurtova, A.M. Gubachikova
Diabetes mellitus and new coronavirus infection: a look into the past, conclusions on prevention and treatment tactics for the future
|
№12 / 2023
|
|
V.I. Petrov, O.V. Shatalova, M.S. Klykova, N.P. Stetsky
The use of sodium-glucose co-transporter type II (SGLT2) inhibitors in patients with chronic heart failure against the background of type 2 diabetes mellitus
|
№12 / 2023
|
|
M.S. Novikova, O.M. Koteshkova, M.B. Antsiferov
Sulodexide: meta-analysis of the treatment of diabetic nephropathy and literature review
|
№12 / 2023
|
|
G.G. Khakimova, M.B. Tashtemirova, A.N. Rakhmonov, M.A. Zhakhongirova
Clinical case of a rare solid pseudopapillary tumor of the pancreas
|
№11 / 2023
|
|
A.A. Gritskevich, T.P. Byteman, D.M. Monakov, I.G. Rusakov, S.V. Mishugin
PARP inhibitors in a personalized approach to the treatment of castration-resistant prostate cancer: clinical case
|
№11 / 2023
|
|
V.F. Semiglazov, P.V. Krivorotko, N.B. Bekkeldieva, A.O. Gorina, A.V. Komyakhov, R.M. Paltuev, T.T. Tabagua, S.S. Ereshenko
Trastuzumab deruxtecan in the treatment of breast cancer
|
№11 / 2023
|
|
O.O. Gordeeva, K.A. Ivanova, A.A. Meshcheryakov
Ceritinib in the treatment of ALK-positive non-small cell lung cancer
|
№11 / 2023
|
|
G.A. Dashyan, E.S. Dzhelialov, V.V. Konstantinova, Yu.A. Gronskaya, A.D. Murskikh, R.M. Akhmedov, A.E. Tyusenko, A.A. Olchonova, Z.V. Dyakonenko, O.A. Sereda, A.M. Belousov
Primary resistance to anti-HER2 therapy: mechanisms of development and ways to overcome
|
№11 / 2023
|
|
T.N. Trofimtseva, S.K. Yarovoy, A.A. Gritskevich
Prevalence of chronic kidney disease among cancer patients
|
№11 / 2023
|
|
N.S. Besova, E.S. Obarevich, A.A. Tryakin, D.A. Gavrilova, S.N. Nered, A.E. Kalinin, I.S. Stilidi
Conversion therapy for disseminated gastric cancer. Interim results of a retrospective analysis of our own data
|
№11 / 2023
|
|
R.V. Orlova, M.I. Gluzman, A.A. Vakhitova
Possibilities of overcoming hormone resistance in patients with metastatic HR+ HER2- breast cancer using the drug alpelisib in various subgroups in real clinical practice
|
№11 / 2023
|
Русский
